Cha Jiyoung Y, Maddileti Savitri, Mitin Natalia, Harden T Kendall, Der Channing J
Lineberger Comprehensive Cancer Center, Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina 27599-7295, USA.
J Biol Chem. 2009 Mar 6;284(10):6227-40. doi: 10.1074/jbc.M803998200. Epub 2008 Dec 22.
Alternative splice variants of fibroblast growth factor receptor 2 (FGFR2) IIIb, designated C1, C2, and C3, possess progressive reduction in their cytoplasmic carboxyl termini (822, 788, and 769 residues, respectively), with preferential expression of the C2 and C3 isoforms in human cancers. We determined that the progressive deletion of carboxyl-terminal sequences correlated with increasing transforming potency. The highly transforming C3 variant lacks five tyrosine residues present in C1, and we determined that the loss of Tyr-770 alone enhanced FGFR2 IIIb C1 transforming activity. Because Tyr-770 may compose a putative YXXL sorting motif, we hypothesized that loss of Tyr-770 in the 770YXXL motif may cause disruption of FGFR2 IIIb C1 internalization and enhance transforming activity. Surprisingly, we found that mutation of Leu-773 but not Tyr-770 impaired receptor internalization and increased receptor stability and activation. Interestingly, concurrent mutations of Tyr-770 and Leu-773 caused 2-fold higher transforming activity than caused by the Y770F or L773A single mutations, suggesting loss of Tyr and Leu residues of the 770YXXL773 motif enhances FGFR2 IIIb transforming activity by distinct mechanisms. We also determined that loss of Tyr-770 caused persistent activation of FRS2 by enhancing FRS2 binding to FGFR2 IIIb. Furthermore, we found that FRS2 binding to FGFR2 IIIb is required for increased FRS2 tyrosine phosphorylation and enhanced transforming activity by Y770F mutation. Our data support a dual mechanism where deletion of the 770YXXL773 motif promotes FGFR2 IIIb C3 transforming activity by causing aberrant receptor recycling and stability and persistent FRS2-dependent signaling.
成纤维细胞生长因子受体2(FGFR2)IIIb的可变剪接变体,命名为C1、C2和C3,其细胞质羧基末端(分别为822、788和769个残基)逐渐缩短,且C2和C3亚型在人类癌症中优先表达。我们确定羧基末端序列的逐渐缺失与转化能力的增强相关。具有高度转化能力的C3变体缺少C1中存在的五个酪氨酸残基,并且我们确定仅缺失Tyr-770就增强了FGFR2 IIIb C1的转化活性。由于Tyr-770可能构成一个假定的YXXL分选基序,我们推测770YXXL基序中Tyr-770的缺失可能导致FGFR2 IIIb C1内化的破坏并增强转化活性。令人惊讶的是,我们发现Leu-773而非Tyr-770的突变损害了受体内化并增加了受体稳定性和激活。有趣的是,Tyr-770和Leu-773的同时突变导致的转化活性比Y770F或L773A单突变高2倍,这表明770YXXL773基序中Tyr和Leu残基的缺失通过不同机制增强了FGFR2 IIIb的转化活性。我们还确定Tyr-770的缺失通过增强FRS2与FGFR2 IIIb的结合导致FRS2的持续激活。此外,我们发现FRS2与FGFR2 IIIb的结合是FRS2酪氨酸磷酸化增加以及Y770F突变增强转化活性所必需的。我们的数据支持一种双重机制,即770YXXL773基序的缺失通过导致异常的受体再循环和稳定性以及持续的FRS2依赖性信号传导来促进FGFR2 IIIb C3的转化活性。